Table 1.
Anticancer activity of the metabolites 1, 2, and 4–7.
| Сompd. | IC50 (μmol/L)a |
SFMCF-7b | SFCT26c | ||
|---|---|---|---|---|---|
| MCF-7 | CT26 | MRC-5 | |||
| Variecolin (1) | 1.4 ± 0.3 | 1.0 ± 0.3 | 1.1 ± 0.2 | 0.8 | 1.1 |
| Variecolactone (2) | 22 ± 8 | 14 ± 3 | 15 ± 3 | 0.7 | 1.1 |
| Variecoladiene (4) | >500 | 409 ± 131 | >500 | – | – |
| 5 | 8 ± 2 | 3.1 ± 0.5 | 11 ± 3 | 1.4 | 3.5 |
| 6 | 117 ± 29 | 60 ± 10 | 33 ± 6 | 0.3 | 0.5 |
| 7 | 30 ± 8 | 19 ± 7 | 14 ± 5 | 0.5 | 0.7 |
| Paclitaxeld | 0.00278 | n.d.e | 0.00261 | 0.9 | – |
a
Half-maximal (50%) inhibitory concentrations in the MCF-7 (human breast adenocarcinoma) and CT26 (murine colon carcinoma) cell lines, as determined using an MTT assay with an exposure time of 72 h. Values are means ± standard deviations obtained from at least three independent experiments.
b
The selectivity factor (SF) was calculated as IC50(MRC-5)/IC50(MCF-7).
c
The SF was calculated as IC50(MRC-5)/IC50(CT26).
d
The IC50 values and SFMCF-7 were taken from the literature45.
e
n.d. = not determined.